United States Drug Patent 9,066,957: Claim Scope, Patent Strength, Exclusivity, and Generic Entry Risk
US 9,066,957 is directed to a low-dose dry powder inhaler containing fluticasone propionate and salmeterol xinafoate with lactose. Its broadest product claim requires both a sub-50 microgram delivered salmeterol dose and a specified bronchodilator response, measured as a baseline-adjusted FEV1 increase of more than 150 mL within 30 minutes. Dependent claims add particle-size specifications, lactose architecture, cyclone deagglomeration, metering-reservoir structures, and treatment uses.
The patent has a fragmented claim estate. Claims 1-18 cover a tightly defined inhaler and treatment combination. Claims 19-20 cover an inhaler dose-measurement procedure that is structurally separate from the pharmaceutical-product limitations. The strongest commercial risk is against a dry powder fluticasone propionate/salmeterol product that uses the claimed low salmeterol dose and materially similar lactose or deagglomeration technology. Conventional Advair Diskus-type products using 50 micrograms of salmeterol per actuation would not literally satisfy the less-than-50-microgram limitation.
What does US 9,066,957 claim?
The patent contains four principal claim groups.
| Claim group |
Claims |
Subject matter |
Commercial relevance |
| Combination inhaler |
1-14 |
Dry powder inhaler containing fluticasone propionate, salmeterol xinafoate, lactose, and specified performance or device characteristics |
High for infringing inhaler products |
| Therapeutic use |
15-18 |
Treatment of asthma, allergic rhinitis, or COPD using the claimed low-dose combination |
Relevant to method-of-use enforcement and regulatory labeling |
| Dose-measurement method |
19-20 |
Sampling, dissolving, filtering, and analyzing an inhaler-delivered dose |
Potentially relevant to testing protocols and laboratory methods |
| Technical subfeatures |
5-14 |
Particle size, lactose fractions, cyclone, reservoir, pressure-relief, and metering structures |
Creates multiple fallback positions but narrows literal infringement |
The independent product claim requires all of the following:
- A dry powder inhaler.
- A dry powder medicament.
- Fluticasone propionate.
- Salmeterol xinafoate.
- A lactose carrier.
- Less than 50 micrograms of delivered salmeterol per actuation.
- A baseline-adjusted FEV1 improvement of more than 150 mL within 30 minutes.
Because claim 1 uses “comprising,” additional excipients, carrier grades, device components, and manufacturing steps generally would not avoid the claim if all recited limitations are present. The claim is narrow in composition and dose, but open-ended as to unrecited components.
How does claim 1 define the core infringement test?
Claim 1 combines structural and clinical-performance limitations. A potentially infringing product must contain the specified drug combination and satisfy the delivered-dose and FEV1 limitations.
The salmeterol limitation concerns delivered dose, not merely the nominal label strength. A product labeled as containing 12.5 micrograms per actuation may deliver a different amount depending on device operation, assay method, storage condition, emitted-dose testing, and patient inhalation. The claim therefore creates a technical dispute over how “delivered dose” is measured.
The FEV1 limitation is more consequential. It requires a response in a patient of more than 150 mL within 30 minutes. Relevant issues would include:
- The baseline used for the adjustment.
- Whether the response must occur in every patient or in a defined study population.
- The statistical endpoint and confidence interval.
- Whether the test must use the claimed inhaler under labeled conditions.
- Whether the claim requires a reproducible product characteristic or merely a clinical result.
- Whether the response must be attributed to the combination, the device, salmeterol, or the interaction of all three.
A generic applicant could argue that the FEV1 limitation is indefinite, insufficiently reproducible, or not inherent in every product falling within the structural limitations. A patent owner would likely argue that the clinical limitation narrows the claim to products producing a defined pharmacodynamic result.
What formulations and particle sizes are protected?
Claims 4-9 add a detailed formulation perimeter.
| Claim |
Limitation |
| 4 |
Fluticasone/salmeterol strengths of 500/12.5, 400/12.5, 250/12.5, 200/12.5, 100/12.5, 50/12.5, or 25/12.5 micrograms per actuation |
| 5 |
Defined fluticasone propionate particle-size distribution |
| 6 |
Defined salmeterol xinafoate particle-size distribution |
| 7 |
Coarse and fine lactose, with fine lactose below 10 micrometers |
| 8 |
Fine lactose at 1-10 weight percent |
| 9 |
Lactose d10 of 15-50 micrometers, d50 of 80-120 micrometers, and d90 of 120-200 micrometers |
Claim 5 contains a drafting issue. It states a fluticasone d50 range of “11.1-3.0 micrometers,” which is presented in descending order and is inconsistent with the ordinary relationship among d10, d50, and d90 values. The likely intended range may be 3.0-11.1 micrometers, but a court would construe the claim from the intrinsic record, prosecution history, specification, and technical context. The wording should not be treated as corrected without reviewing those materials.
Claim 6 is internally more conventional: d10 is 0.4-1.3 micrometers, d50 is 1.4-3.0 micrometers, and d90 is 2.4-6.5 micrometers. The requirement that 95% or more of particles be below 10 micrometers is relevant to respirable performance and may distinguish larger-particle formulations.
The lactose limitations are commercially important because lactose is not merely an inactive filler in the claim set. The claimed combination requires a coarse carrier population and, in claims 7-8, a separate fine-lactose fraction. A product using lactose outside the recited size ranges, or using a non-lactose carrier, may avoid these dependent claims while remaining exposed under claim 1.
What inhaler devices fall within the claims?
Claims 10-14 extend protection beyond the formulation.
Cyclone deagglomerator
Claims 10-11 require a cyclone deagglomerator with:
- An axially extending swirl chamber.
- A powder supply port.
- One or more inlet ports in the inner wall.
- An outlet port.
- Vanes with oblique surfaces.
- Breath-induced air flow through the supply and inlet ports.
This is a detailed apparatus limitation. A generic inhaler using a different deagglomeration mechanism, such as a simple impactor, grid, mesh, turbulent channel, or non-cyclonic chamber, may avoid claims 10-11. The limitation may still be relevant where a device’s internal geometry is not publicly disclosed and must be established by teardown or discovery.
Metered reservoir
Claim 12 covers an inhaler with a medicament reservoir and an arrangement for delivering a metered dose. This is broader than claim 11 and could reach multiple reservoir-based dry powder devices.
Claim 14 is materially narrower. It requires a sealed reservoir, dispensing port, channel, pressure-relief port, conduit, and movable cup assembly with first and second sealing surfaces. The cup must seal and unseal the ports in a defined sequence. This claim is directed to a particular pressure-management and dose-metering architecture, not to every reservoir inhaler.
Delivery passageway and channel
Claim 13 requires a delivery passageway leading to a mouthpiece and a channel extending from the passageway to the medicament. It may cover a range of inhaler geometries, but its scope depends on construction of “channel” and the relationship between the channel, powder bed, and air path.
What treatment methods are protected?
Claims 15-18 cover administration for asthma, allergic rhinitis, or COPD. Claims 16-18 repeat the low-dose and FEV1 requirements of claim 1.
The method claims are narrower than a general claim to treating respiratory disease with fluticasone and salmeterol. They require the claimed formulation and the specified delivered salmeterol dose. Claim 18 also lists specific fluticasone/salmeterol dose combinations.
The allergic-rhinitis indication is notable because fixed-dose inhaled fluticasone propionate/salmeterol products are principally associated with asthma and COPD. A product label directed only to allergic rhinitis could raise separate questions concerning approved use, clinical support, and induced infringement. A label that expressly promotes a claimed use creates greater method-of-use exposure than a label limited to nonclaimed indications.
How strong are claims 19 and 20?
Claims 19-20 cover a method for measuring delivered active agent by:
- Inserting the inhaler into a mouthpiece adapter.
- Actuating the inhaler into a dosage-unit sampling apparatus.
- Rinsing the adapter into the apparatus.
- Dissolving the dose.
- Filtering the solution.
- Analyzing the filtered solution.
- Repeating the test at the beginning, middle, and end of inhaler life under claim 20.
These claims are not expressly limited to fluticasone propionate, salmeterol xinafoate, lactose, or the claimed FEV1 result. Their breadth creates potential validity and enforcement issues. Prior-art delivered-dose testing methods, USP procedures, regulatory aerosol testing protocols, and standard laboratory workflows could be relevant under 35 U.S.C. §§ 102 and 103.
Claim 20 adds the lifecycle sampling requirement. It may be useful where a manufacturer’s release and stability protocol tests beginning-, middle-, and end-of-life performance. It is less likely to control ordinary patient use because patients generally do not conduct the specified laboratory procedure.
When does US 9,066,957 lose exclusivity?
The patent’s expiration date cannot be calculated from the claim text or issue number alone. US 9,066,957 issued on June 23, 2015, but US patent term generally runs 20 years from the effective nonprovisional or PCT filing date, subject to patent term adjustment, patent term extension, terminal disclaimers, and any applicable transitional rules. The issue date is not the ordinary term endpoint. 35 U.S.C. § 154.
A reliable term analysis requires the USPTO continuity and prosecution record. The relevant date is the earliest effective filing date for the claimed subject matter, not necessarily the earliest provisional priority date. Patent term adjustment may move the expiration date forward; a terminal disclaimer may move it backward.
The patent number itself does not establish FDA regulatory exclusivity. Patent exclusivity and FDA exclusivity are separate rights.
What is the Orange Book status?
A patent is not automatically listed in the FDA Orange Book because it covers an inhaler or pharmaceutical formulation. Orange Book listing depends on submission by the NDA holder and FDA’s determination that the patent claims the approved drug, an approved method of use, or a relevant drug-delivery system under FDA listing rules. The Orange Book identifies patents and exclusivity associated with approved drug products, while the patent document establishes the legal claims. FDA, Approved Drug Products with Therapeutic Equivalence Evaluations.
The supplied claims do not establish that US 9,066,957 is listed against Advair, AirDuo, Wixela Inhub, or another approved product. A product-specific Orange Book conclusion cannot be drawn from the claim language alone.
If listed against an NDA product, the patent could affect an ANDA through:
- A Paragraph IV certification alleging invalidity, unenforceability, or noninfringement.
- A Section viii statement where the applicant omits a listed method of use.
- A 30-month stay if the NDA holder or patent owner brings timely litigation under 21 U.S.C. § 355(j)(5)(B)(iii).
A device or formulation claim may be more difficult to omit through a Section viii statement if the approved product itself embodies the claimed structure.
Which competing products create the greatest risk?
| Product category |
Active ingredients |
Relationship to the claims |
| Advair Diskus and authorized or generic equivalents |
Fluticasone propionate/salmeterol |
Potential composition overlap, but conventional 50-microgram salmeterol strengths may not meet the less-than-50-microgram limitation |
| Advair HFA |
Fluticasone propionate/salmeterol |
Pressurized metered-dose inhaler, not a dry powder inhaler; generally outside claim 1 |
| AirDuo RespiClick |
Fluticasone propionate/salmeterol |
Directly relevant because it is a low-dose dry powder combination with a breath-actuated device |
| Wixela Inhub |
Fluticasone propionate/salmeterol |
Relevant dry powder competitor; infringement depends on dose, formulation, particle size, carrier, and internal device structure |
| Breo Ellipta |
Fluticasone furoate/vilanterol |
Does not contain the claimed active ingredients |
| Symbicort |
Budesonide/formoterol |
Does not contain the claimed active ingredients |
| Dulera |
Mometasone/formoterol |
Does not contain the claimed active ingredients |
AirDuo and Wixela are more relevant than Breo, Symbicort, or Dulera because they use fluticasone propionate/salmeterol. Even then, literal infringement requires satisfaction of the specific claim limitations. A product may share the active ingredients but avoid the patent through a different salmeterol dose, carrier, particle-size profile, deagglomerator, reservoir design, or clinical-performance profile.
What generic launch scenarios exist?
Scenario 1: Conventional 50-microgram salmeterol product
A dry powder product delivering 50 micrograms of salmeterol per actuation has a strong noninfringement position against the “less than 50 micrograms” limitation in claims 1-4 and 16-18, subject to construction of the dose measurement and rounding conventions.
Scenario 2: Low-dose dry powder product
A product delivering 12.5 or 14 micrograms of salmeterol is closer to the asserted scope. Risk increases if it also uses lactose, the listed particle-size distributions, fine lactose, or a claimed cyclone or metering system.
Scenario 3: Same drugs, different device
A product using the claimed active ingredients and dose but a different inhaler architecture may remain exposed under claim 1 if it meets the FEV1 limitation. It may avoid claims 10-14.
Scenario 4: Same device, different formulation
A device with the claimed cyclone or reservoir technology but a different active ingredient combination would generally fall outside claims 1-18. Claims 19-20 could remain relevant if the testing method is practiced.
Scenario 5: Non-literal or induced infringement theory
The FEV1 limitation and laboratory-test claims create potential disputes over inherent infringement, inducement, and proof. The patent owner would need reliable product testing, clinical evidence, device inspection, or documentary evidence linking the accused product to the claimed limitations. 35 U.S.C. § 271.
How does the patent compare with the broader fluticasone/salmeterol landscape?
US 9,066,957 is narrower than a basic composition patent covering fluticasone propionate and salmeterol. Its commercial value lies in the combination of low delivered salmeterol dose, dry powder delivery, and performance-defined bronchodilation.
Its coverage is also narrower than a broad device patent covering all inhalers with cyclone deagglomerators or metered reservoirs. The claims require the device limitations to be combined with the specific drug product through dependency on claim 1.
The estate is therefore best characterized as:
| Dimension |
Assessment |
| Active-ingredient coverage |
Narrow |
| Dose coverage |
Narrow and potentially valuable for low-dose products |
| Formulation coverage |
Moderate where particle and lactose ranges are met |
| Device coverage |
Detailed and architecture-specific |
| Method-of-use coverage |
Narrow but potentially relevant to labeled indications |
| Assay-method coverage |
Broad relative to claims 1-18, but vulnerable to prior art |
| Design-around potential |
Meaningful |
| Biosimilar exposure |
None in the conventional sense; this is a small-molecule combination |
| Generic exposure |
Significant if a low-dose dry powder product is developed |
What manufacturing and intellectual-property barriers remain?
The principal manufacturing barriers are control of:
- Drug particle-size distributions.
- Drug-to-lactose adhesion and detachment.
- Fine-lactose content.
- Delivered-dose uniformity.
- Device deagglomeration efficiency.
- Reservoir filling and metering accuracy.
- Dose performance over the inhaler’s labeled life.
These technical parameters may be difficult to design around while preserving equivalent lung delivery. A noninfringing product could use a different carrier, a different particle engineering process, a different metering chamber, or a different airflow path. Regulatory comparability and in-vitro performance requirements may limit the commercial attractiveness of some alternatives even where patent avoidance is technically possible.
Key Takeaways
- US 9,066,957 targets a low-dose dry powder fluticasone propionate/salmeterol inhaler.
- Claim 1 requires less than 50 micrograms of delivered salmeterol and an FEV1 improvement above 150 mL within 30 minutes.
- Claims 4 and 16-18 focus on low-dose strengths, including 12.5-microgram salmeterol combinations.
- Claims 5-9 add particle-size and lactose-carrier limitations.
- Claims 10-14 cover specific cyclone, reservoir, pressure-relief, and metering structures.
- Claims 19-20 cover a separate delivered-dose assay procedure.
- Conventional 50-microgram salmeterol products may have a strong noninfringement argument against the principal dose limitation.
- AirDuo and Wixela-type dry powder products are more relevant competitive comparators than products using different active ingredients or pressurized aerosol delivery.
- The patent number does not establish Orange Book listing, litigation status, settlement status, or expiration date.
- Patent term must be calculated from the prosecution and continuity record, not the June 23, 2015 issue date.
- The claim set presents meaningful design-around opportunities but can create high risk for a low-dose dry powder product using the same formulation and device architecture.
FAQs
Does US 9,066,957 cover Advair HFA?
Generally, claim 1 requires a dry powder inhaler, while Advair HFA is a pressurized metered-dose inhaler. Advair HFA would not ordinarily satisfy the dry powder limitation.
Does US 9,066,957 cover Breo Ellipta?
No literal composition coverage is apparent because Breo Ellipta contains fluticasone furoate and vilanterol, whereas the claims require fluticasone propionate and salmeterol xinafoate.
Can a generic avoid the patent by using 14 micrograms of salmeterol?
Not automatically. A 14-microgram product remains below 50 micrograms and could fall within claim 1 if all other limitations, including the FEV1 result, are met. It may avoid the specific 12.5-microgram alternatives in claims 4 and 18.
Is a lactose-free fluticasone/salmeterol inhaler outside the claims?
It would likely avoid claims requiring a lactose carrier, including claim 1, if lactose is truly absent. The product would still require separate analysis under any unrelated patent claims covering the active ingredients or device.
Are claims 19-20 relevant to a generic applicant’s routine testing?
They can be relevant if the applicant performs the claimed sequence using the specified adapter, sampling apparatus, rinsing, dissolution, filtration, analysis, and lifecycle testing steps. Their breadth and validity would depend heavily on the prior art and the precise laboratory protocol used.
References
-
United States Patent No. 9,066,957, claims 1-20, claim text supplied in the request.
-
United States Code, Title 35, § 154. Patent term.
-
United States Code, Title 35, § 271. Infringement of patent.
-
United States Code, Title 35, § 112. Specification requirements.
-
United States Code, Title 21, § 355(j). Abbreviated new drug applications and patent certifications.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book).
-
U.S. Patent and Trademark Office. (2024). Manual of Patent Examining Procedure, § 2111, Claim interpretation; broadest reasonable interpretation.
